Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varoglutamstat - Vivoryon Therapeutics

Next Previous
Drug Profile

Varoglutamstat - Vivoryon Therapeutics

Alternative Names: PQ-912; SIM 0408; SIM-0801

Latest Information Update: 06 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Probiodrug
  • Developer University of California, San Diego; Vivoryon Therapeutics
  • Class Anti-inflammatories; Antidementias; Benzimidazoles; Imidazolidines; Neuroprotectants; Small molecules
  • Mechanism of Action Glutaminyl-peptide cyclotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • No development reported Huntington's disease; Inflammation

Most Recent Events

  • 04 Mar 2024 Efficacy and adverse events data from a phase II trial in Alzheimer's disease released by Vivoryon Therapeutics
  • 12 Jan 2024 Vivoryon Therapeutics completes a phase II VIVIAD trial in Alzheimer's disease in Denmark, Germany, Netherlands, Poland and Spain (PO) (NCT04498650)
  • 06 Dec 2023 Vivoryon anticipates to conduct an end of phase II meeting with the U.S. Food and Drug Administration (FDA) in the second half of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top